Research indicates that DNA patterns could detect the progression of certain blood cancers years before standard tests. The study, featured in Cancer Discovery, tracked 30 individuals with myeloproliferative neoplasms (MPNs). These blood cancers involve the bone marrow producing excessive blood cells.
Scientists observed DNA changes in the patients’ blood and bone marrow, assessing if these changes were connected to blood counts, disease stability, or advancement to myelofibrosis or acute leukemia. According to the Wellcome Trust Sanger Institute in the U.K., patients with stable disease often displayed stable DNA with minimal cancer-related genetic changes.
Participants whose conditions worsened typically showed DNA changes years before the disease progressed according to standard blood tests. New groups of abnormal cells emerged over time. Nine individuals eventually acquired acute myeloid leukemia (AML); however, the disease progression varied.
In some patients, MPN cells accumulated harmful mutations gradually. In others, leukemia appeared to develop from a distinct group of abnormal blood cells. Similar patterns emerged in those who developed myelofibrosis.
The research identified that hydroxyurea, a common MPN treatment, created a recognizable pattern of minor DNA changes in blood cells. Despite these changes, there was no evidence suggesting the drug leads to leukemia. Azacitidine, another drug for treating certain blood cancers, showed a similar pattern.
Interestingly, participants with “triple-negative” essential thrombocythemia lacked genetic cancer evidence. This finding raises the possibility that some individuals with this diagnosis might not require prolonged cancer treatment.
Though the study had a limited sample size, the findings highlight associations rather than cause and effect. Dr. Abhishek Chilkulwar, an oncologist with Orlando Health, emphasized that many people with MPNs can live for decades. He described the findings as a notable indication that DNA changes could predict cancer development and progression well before symptoms appear.
He further discussed the potential of precision medicine in blood cancer care. This approach might use genetic data to forecast risk and intervene before disease progression instead of addressing it post-diagnosis. The research implies that regular DNA testing over time could provide early warnings of disease progression.
The next development phase involves associating early genetic insights with drugs targeting specific mutations. This strategy aims to prevent or delay disease progression. However, current practical applications involve closer monitoring, not new treatments.
For instance, detecting a high-risk mutation in a patient could lead to more frequent blood counts or bone marrow checks to catch any progression early. However, these findings do not immediately warrant stem cell transplant evaluations, which should be considered only for patients with advanced conditions like myelofibrosis or AML.
Dr. Chilkulwar highlighted the significance of future research pairing early genetic detection with targeted treatments, potentially preventing or delaying disease advance.